ALS Program
Amyotrophic Lateral Sclerosis
Multiple PhasesActive
Key Facts
About Biogen
Biogen stands as a premier biotechnology company focused on developing innovative therapies for complex neurological, immunological, and rare diseases with significant unmet medical needs. With decades of pioneering work in multiple sclerosis and recent expansions into nephrology through the acquisition of Human Immunology Biosciences, the company maintains a diverse pipeline spanning Alzheimer's disease, ALS, lupus, and other challenging conditions. Biogen's commitment to scientific excellence is demonstrated through substantial annual R&D investment of $2 billion and a global team of over 1,300 research professionals driving innovation from discovery to commercialization.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Reldesemtiv | Cytokinetics | Phase 3 |